Smoking characteristics and cessation in patients with thromboangiitis obliterans

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 65, Issue 4, 2006, Pages 217-221

  Jiménez Ruiz, Carlos A ^a   Dale, L C ^b   Mochales, J Astray ^a   Velazquez Buendia L ^a   de Granda Orive, I ^c   García, A Guirao ^a  

^a Madrileño Institute of Public Health   (Spain)

^b MAYO CLINIC   (United States)

^c Hospital de la Defensa   (Spain)

Author keywords

Buerger's Disease; Smoking cessation; Thromboangiitis obliterans

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; NICOTINE PATCH;

ADULT; AMPUTATION; ARTICLE; BEHAVIOR THERAPY; BUERGER DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; DRUG EFFICACY; EXPIRED AIR; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MALE; PATIENT COUNSELING; PREVALENCE; PRURITUS; RASH; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SMOKING HABIT; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

EID: 33947414847     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: 10.4081/monaldi.2006.552     Document Type: Article

References (20)

1. Olin JW. Current concepts: Thromboangiitis Obliterans (Buerger's Disease). New Engl J Med 2000; 343:864-869.
2. Papa MZ, Adar R. A critical look at Thromboangiitis Obliterans (Buerger's Disease). Vasc Surg 1992; 5: 1-18.
3. O'dell JR, Linder J, Markin RS, Moore GF. Thromboangiitis Obliterans (Buerger's Disease) and smokeless tobacco. Arth Rheum 1987; 30: 1054-1056.
4. Shionoya S. What is Buerger's Disease? World J Surg 1983; 7: 544-551.
5. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The changing clinical spectrum of Thromboangiitis Obliterans (Buerger's Disease). Circulation 1990; 82: Suppl IV: 8.
6. Joyce JW. Buerger's Disease (Thromboangiitis Obliterans). Rheum Dis Clin North Am 1990; 16: 463-470.
7. Mills JL, Taylor LM, Poter JM. Buerger's Disease in the modem era. Am J Surg 1987; 154: 123-129.
8. Grove WJ, Stansby GP. Buerger's Disease and cigarette smoking in Bangladesh. Ann Royal College Surg Engl 1992; 74: 115-117.
9. Jiménez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: Differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365-1370.
10. Barrueco M, Jiménez-Ruiz CA, Palomo L, Torecilla M, Romero M, Riesco JA. Abstinencia continua y puntual en el tratamiento farmacológico del tabaquismo en la práctica clínica. Med Clin (Barc) 2004; 123: 662-6.
11. Dale LC, Glover ED, Sachs DP, et al. Bupropion for smoking cessation. Predictors of successful outcome. Chest 2001, 119: 1357-1364.
12. George TP, O'Malley SS. Current pharmacological treatment for nicotine dependence. Trends Pharm Sci 2004; 25: 42-48.
13. Barrueco M, Jiménez-Ruiz CA, Palomo L, Torecilla M, Romero M, Riesco JA. Adverse effects of pharmacologic treatment for nicotine addiction. Nicotine Tob Res 2005; 7: 335-42.
14. Lie JT. Thromboangiitis Obliterans (Buerger's Disease) and smokeless tobacco. Arth Rheum 1988; 31: 812-813.
15. Hooten MW, Bruns HK, Hays JT. Inpatient treatment of severe nicotine dependence in a patient with Thromboangiitis Obliterans (Buerger's Disease). Mayo Clinic Proc 1998; 73: 529-532.
16. Rennard SI, Daughton D, Windle J. Toxicity of nicotine replacement in patients with coronary artery disease. In Nicotine safety and toxicity. Benowitz NL (ed). New York Oxford. Oxford University Press. 1998; pp: 49-53.
17. Working Group for the study of Transdermal Nicotine in patients with coronary artery disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994; 154: 989-95
18. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy: Percentage of replacement and smoking cessation. JAMA 1995; 274: 1353-1358.
19. Hurt RD, Dale LC, Offord KP, Bruce KP, McClain FL, Eberman KM. Inpatient treatment of severe nicotine dependence. Mayo Clinic Proc 1992; 67: 823-8.
20. John U, Meyer C, Hapke U, Rumpf HL, Schumann A, Adam C, Alte D, Ludemann J. The Fagerström test for nicotine dependence in two adults population samples-potential influence of lifetime amount of tobacco smoked on the degree of dependence. Drug Alcohol Depend 2003; 71: 1-6.